Alexion Receives International Investor Award 2016

On July 7, Alexion was honored with a 2016 International Investor Award from the Greater Paris Investment Agency (Paris-Ile de France Capitale Economique) for its significant investment and growth in Paris, France. Alexion first established its presence in France in 2005 and, in 2015, opened a new Research and Development Center in Paris – its first European research hub for rare and severe diseases. The state-of-the-art R&D Center aims to advance the understanding of devastating and rare diseases, in addition to facilitating the discovery of life-transforming therapies for patients suffering from these disorders.

“We are pleased to accept this award from the Greater Paris Investment Agency and proud to be one of the few companies researching and developing therapies to treat rare and ultra-rare diseases. Our R&D Center in Paris plays a critical role in helping to achieve our mission to transform the lives of patients globally who suffer from severe and rare disorders,” said Martin Mackay, Ph.D., Executive Vice President and Head of R&D at Alexion. “As a global R&D leader, it is critically important to have a center of excellence in R&D for rare diseases in Europe, and Paris is an attractive location, with its large pool of highly talented life-science professionals and long track record of scientific excellence.”

The Greater Paris Investment Agency honors three companies annually with an International Investor Award based on their contribution to driving investment, employment and development in Paris and the region. “We are pleased to be honoring, this year, an innovative biotech company with an International Investor Award, acknowledging Alexion’s contribution to advancing research and science for patients with rare diseases where there is significant unmet medical need,” said Christian Nibourel, President of the Greater Paris Investment Agency (Paris-Ile de France Capitale Economique). “Life-sciences are an important sector for the Greater Paris area and we believe this research commitment showcases the continued growth of the industry in the region.”

Alexion’s R&D Center Paris, which is located at the campus of the Necker Hospital at the Imagine Institute, focuses on discovery research activities in the fields of cell and molecular biology, genomics, and immunogenicity. Alexion plans to pursue additional collaborations with other leading hospitals and research centers in France and throughout Europe. Alexion’s breakthrough medical innovation has been recognized worldwide; in 2009, Alexion was proud to receive the Prix Galien in France for its first product to market, Soliris® (eculizumab), in the category of drugs for rare diseases.